A randomized, parallel-group, phase II study to evaluate the efficacy and safety of three doses of the integrin inhibitor cilengitide compared with docetaxel in patients with stage IV non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy
JOURNAL OF THORACIC ONCOLOGY(2009)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要